KR20240166514A - 순환하는 단백질의 선택적인 분해를 표적화하는 이작용성 소 분자 - Google Patents

순환하는 단백질의 선택적인 분해를 표적화하는 이작용성 소 분자 Download PDF

Info

Publication number
KR20240166514A
KR20240166514A KR1020247034017A KR20247034017A KR20240166514A KR 20240166514 A KR20240166514 A KR 20240166514A KR 1020247034017 A KR1020247034017 A KR 1020247034017A KR 20247034017 A KR20247034017 A KR 20247034017A KR 20240166514 A KR20240166514 A KR 20240166514A
Authority
KR
South Korea
Prior art keywords
alkyl
disease
group
compound
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034017A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 스피겔
데이비드 카이아니엘로
멩웬 장
Original Assignee
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed by 예일 유니버시티 filed Critical 예일 유니버시티
Publication of KR20240166514A publication Critical patent/KR20240166514A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247034017A 2022-03-15 2023-03-15 순환하는 단백질의 선택적인 분해를 표적화하는 이작용성 소 분자 Pending KR20240166514A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/695,645 2022-03-15
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (1)

Publication Number Publication Date
KR20240166514A true KR20240166514A (ko) 2024-11-26

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034017A Pending KR20240166514A (ko) 2022-03-15 2023-03-15 순환하는 단백질의 선택적인 분해를 표적화하는 이작용성 소 분자

Country Status (8)

Country Link
EP (1) EP4493222A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025509730A (cg-RX-API-DMAC7.html)
KR (1) KR20240166514A (cg-RX-API-DMAC7.html)
CN (1) CN119255822A (cg-RX-API-DMAC7.html)
AU (1) AU2023236291A1 (cg-RX-API-DMAC7.html)
IL (1) IL315579A (cg-RX-API-DMAC7.html)
MX (1) MX2024011338A (cg-RX-API-DMAC7.html)
WO (1) WO2023178202A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CA3134765A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
EP3897747A4 (en) * 2018-12-19 2022-12-07 The Board of Trustees of the Leland Stanford Junior University BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS
MX2022009419A (es) * 2020-01-31 2022-08-25 Avilar Therapeutics Inc Compuestos de union al asgpr para la degradacion de proteinas extracelulares.

Also Published As

Publication number Publication date
MX2024011338A (es) 2024-12-06
CN119255822A (zh) 2025-01-03
WO2023178202A2 (en) 2023-09-21
JP2025509730A (ja) 2025-04-11
WO2023178202A3 (en) 2023-10-26
AU2023236291A1 (en) 2024-10-03
IL315579A (en) 2024-11-01
EP4493222A2 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
US20250332274A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
US20240083859A1 (en) Bi-functional Molecules To Degrade Circulating Proteins
US12485178B2 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
KR20250007063A (ko) 표적화된 이작용성 분해제
US20250205343A1 (en) Bi-functional molecules to degrade circulating proteins
AU2023236291A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
EA039074B1 (ru) Жирные кислоты и их конъюгаты с биомолекулами
UA127808C2 (uk) Похідна пладієноліду (варіанти) як засіб, що здійснює цілеспрямований вплив на сплайсосому, для лікування раку
AU2024264049A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
CA2934617A1 (en) Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
KR20250004953A (ko) 순환하는 단백질을 분해하기 위한 이-작용성 분자
WO2025149012A1 (zh) Dolastatin衍生物及其制备方法和应用
HK40042237A (en) Bifunctional small molecules to target the selective degradation of circulating proteins
WO2024067477A1 (zh) 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
KR20260003654A (ko) 관절염의 치료, 개선, 또는 예방을 위한 화합물 및 방법
KR20260066104A (ko) Gpc3을 표적으로 하는 항체-약물 접합체 및 이의 응용

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000